Hemangeol Solution
NDC Package 64370-375-01
Package Information
Hemangeol (propranolol hydrochloride) solution is this formulation of propranolol is used for infants and children to treat a certain benign tumor (proliferating infantile hemangioma). This formulation utilizes a solution delivery system. Marketed by Pierre Fabre Pharmaceuticals, Inc., this product is identified by NDC 64370-375 and is authorized under FDA application NDA205410.
Identification & Billing
- RxCUI: 1495058 - propranolol HCl 4.28 MG in 1 mL Oral Solution
- RxCUI: 1495058 - propranolol hydrochloride 4.28 MG/ML Oral Solution
- RxCUI: 1495058 - propranolol HCl 4.28 MG/ML (as propranolol 3.75 MG/ML) Oral Solution
- RxCUI: 1495058 - propranolol hydrochloride 4.28 MG per 1 ML Oral Solution
- RxCUI: 1495064 - Hemangeol 4.28 MG in 1 mL Oral Solution
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 64370 - Pierre Fabre Pharmaceuticals, Inc.
- 64370-375 - Hemangeol
- 64370-375-01 - 1 BOTTLE, GLASS in 1 CARTON / 120 mL in 1 BOTTLE, GLASS
- 64370-375 - Hemangeol
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (64370-375). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 64370-375-01 identifies a specific commercial package of 1 bottle, glass in 1 carton / 120 ml in 1 bottle, glass of Hemangeol, a human prescription drug labeled by Pierre Fabre Pharmaceuticals, Inc.. This solution is formulated for oral use and contains propranolol hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Pierre Fabre Pharmaceuticals, Inc. on April 14, 2014. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This formulation of propranolol is used for infants and children to treat a certain benign tumor (proliferating infantile hemangioma). It helps to shrink the tumor. Propranolol belongs to a class of drugs known as beta blockers.
How is this Pierre Fabre Pharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 64370037501. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.